Clinical trial
Phase 2 Study of Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE)
NCT04985825 is registered in ClinicalTrials.gov with Pega-One S.A.S. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study of Imgatuzumab in Patients With Advanced Cutaneous Squamous Cell Carcinoma (I-PACE)
- Lead sponsor
- Pega-One S.A.S.
- Phase
- Phase 2
- Overall status
- Withdrawn
- Start date
- December 16, 2021
- Completion date
- August 17, 2022
- Enrollment
- 0 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.